Retatrutide 60mg

Retatrutide 60mg Pen refers to an investigational, injectable medication for weight loss, a triple-agonist targeting GIP, GLP-1, and glucagon receptors, showing significant weight reduction in trials by reducing appetite and increasing metabolism, available in pre-filled pens for weekly subcutaneous use, though still under development and not yet FDA-approved for general use. Suppliers in India offer it in pen form for research/export, often citing 12mg strength pens with potential doses up to 60mg or more, mimicking similar drugs like Ozempic but with a triple-hormone approach for potentially greater efficacy.

What it is

A Triple-Agonist: It mimics three natural gut hormones (GIP, GLP-1, and glucagon) to control hunger, slow digestion, and boost fat burning.

Investigational Drug: Still in clinical trials (Phase 3), not approved by regulatory bodies like the FDA for public use

yet.

How it's used

Weekly Injection: Administered once a week under the skin (subcutaneously).

Pen Device: Comes in a pen format for easier dosing, similar to Ozempic or Mounjaro.

Dosage: Doses studied range from 1 mg to 12mg, with higher doses potentially leading to greater weight loss.

What it does

Significant Weight Loss: Phase 2 trials showed average weight loss of over 20% in 48 weeks.